

syndrome). Baby pigs: an aid in the prevention and treatment of selenium-tocopherol deficiency.

(iii) *Limitations*. For subcutaneous or intramuscular use only. Discontinue use 14 days before treated animals are slaughtered for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[40 FR 13858, Mar. 27, 1975, as amended at 52 FR 7832, Mar. 13, 1987; 57 FR 21209, May 19, 1992; 58 FR 57556, Oct. 26, 1993; 60 FR 57833, Nov. 22, 1995; 64 FR 27916, May 24, 1999]

§ 522.2112 Sometribove zinc suspension.

(a) *Specifications*. Each single-dose syringe contains 500 milligrams (mg) sometribove zinc in a prolonged-release suspension.

(b) *Sponsor*. See No. 000986 in § 510.600(c) of this chapter.

(c) *Conditions of use*—(1) *Amount*. Inject 500 mg every 14 days starting during the 9th or 10th week (57 to 70 days) after calving and continue until the end of lactation.

(2) *Indications for use*. To increase production of marketable milk in healthy lactating dairy cows.

(3) *Limitations*. Use in lactating dairy cows only. Safety to replacement bulls born to treated dairy cows has not been established. Inject subcutaneously. Avoid injections within 2 weeks of expected slaughter to minimize injection site blemishes on carcass. There is no milk discard or preslaughter withdrawal period. Use may reduce pregnancy rates and increase days open. Treated cows are at an increased risk for mastitis and higher milk somatic cell counts. Use care to differentiate increased body temperature due to use of this product from an increased body temperature that may occur due to illness. Cows treated with this product may have more enlarged hocks and disorders of the foot region. Use may reduce hemoglobin and hematocrit values during treatment. Human warning: Avoid prolonged or repeated contact with eyes and skin.

[58 FR 59947, Nov. 12, 1993, as amended at 67 FR 18085, Apr. 15, 2002; 68 FR 62006, Oct. 31, 2003; 74 FR 53164, Oct. 16, 2009]

§ 522.2120 Spectinomycin dihydrochloride injection.

(a) *Specifications*. The spectinomycin dihydrochloride pentahydrate used in manufacturing the drug is the antibiotic substance produced by the growth of *Streptomyces flavopersicus* (var. Abbott) or the same antibiotic substance produced by any other means. Each milliliter of the drug contains the following amount of spectinomycin activity from spectinomycin dihydrochloride pentahydrate:

(1) 5 milligrams when used as provided in paragraph (d)(1) of this section.

(2) [Reserved]

(3) 100 milligrams when used as provided in paragraphs (d) (2), (3), and (4) of this section.

(b) *Sponsor*. In § 510.600 of this chapter, see No. 059130 for conditions of use as in paragraph (d) of this section, and see No. 000009 for conditions of use as in paragraph (d)(2) and (d)(4) of this section.

(c) *Special considerations*. The quantity of spectinomycin referred to in this section refers to the equivalent weight of base activity for the drug.

(d) *Conditions of use*. It is administered as spectinomycin dihydrochloride pentahydrate as follows:

(1) Subcutaneously in the treatment of 1-to-3-day-old turkey poults at the rate of 1 to 2 milligrams per poult as an aid in the prevention of mortality associated with Arizona group infection.

(2) Subcutaneously in the treatment of 1-to-3-day old:

(i) Turkey poults at the rate of 5 milligrams per poult as an aid in the control of chronic respiratory disease (CRD) associated with *E. coli*.

(ii) Baby chicks at the rate of 2.5 to 5 milligrams per chick as an aid in the control of mortality and to lessen severity of infections caused by *M. synoviae*, *S. typhimurium*, *S. infantis*, and *E. coli*.

(3) Intramuscularly in the treatment of dogs:

(i) At a dosage level of 2.5 milligrams to 5.0 milligrams per pound of body weight twice daily. Treatment may be continued for 4 days. For treatment of infections caused by gram-negative and

§ 522.2121

gram-positive organisms susceptible to spectinomycin.

(ii) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

(4) Administer single injection of 0.1 milliliter (10 milligrams) subcutaneously in nape of neck of 1- to 3-day-old turkey poults as an aid in control of airsacculitis associated with *M. meleagridis* sensitive to spectinomycin.

[40 FR 13858, Mar. 27, 1975, as amended at 43 FR 9273, Mar. 7, 1978; 46 FR 18964, Mar. 27, 1981; 47 FR 14149, Apr. 2, 1982; 61 FR 5507, Feb. 13, 1996; 61 FR 31028, June 19, 1996; 65 FR 45877, July 26, 2000; 66 FR 22118, May 3, 2001]

§ 522.2121 Spectinomycin sulfate.

(a) *Specifications.* Each milliliter of solution contains spectinomycin sulfate tetrahydrate equivalent to 100 milligrams (mg) spectinomycin.

(b) *Sponsor.* See No. 000009 in § 510.600(c) of this chapter.

(c) *Related tolerances.* See § 556.600 of this chapter.

(d) *Conditions of use in cattle*—(1) *Amount.* 10 to 15 mg per kilogram of body weight at 24-hour intervals for 3 to 5 consecutive days.

(2) *Indications for use.* For the treatment of bovine respiratory disease (pneumonia) associated with *Mannheimia haemolytica*, *Pasteurella multocida*, and *Histophilus somni*.

(3) *Limitations.* Do not slaughter within 11 days of last treatment. Do not use in female dairy cattle 20 months of age or older. Use in this class of cattle may cause residues in milk. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[72 FR 31178, June 6, 2007]

§ 522.2150 Stanozolol sterile suspension.

(a) *Specifications.* Each milliliter of sterile suspension contains 50 milligrams of stanozolol.

(b) *Sponsor.* No. 000009 in § 510.600(c) of this chapter.

(c) *Conditions of use.* (1) Used as an anabolic steroid treatment in dogs, cats, and horses.

21 CFR Ch. I (4–1–12 Edition)

(2) Administered to dogs and cats by deep intramuscular injection in the thigh at weekly intervals, for several weeks. For cats and small breeds of dogs, 25 milligrams. For larger dogs, 50 milligrams.

(3) Administered to horses by deep intramuscular injection in the gluteal region at weekly intervals, for not more than 4 weeks; 25 milligrams per 100 pounds of body weight.

(4) Not for use in horses intended for food.

(5) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

[40 FR 46101, Oct. 6, 1975, as amended at 42 FR 36995, July 19, 1977; 55 FR 23076, June 6, 1990]

§ 522.2200 Sulfachlorpyridazine.

(a) *Specifications.* Each milliliter of solution contains sodium sulfachlorpyridazine equivalent to 200 milligrams (mg) sulfachlorpyridazine.

(b) *Sponsor.* See No. 000010 in § 510.600(c) of this chapter.

(c) *Related tolerances.* See § 556.630 of this chapter.

(d) *Conditions of use in calves.* It is used as follows:

(1) *Amount.* Administer 30 to 45 mg per pound (1b) of body weight in divided doses by twice daily injection for 1 to 5 days.

(2) *Indications for use.* For the treatment of diarrhea caused or complicated by *Escherichia coli* (colibacillosis).

(3) *Limitations.* Treated calves must not be slaughtered for food during treatment or for 5 days after the last treatment. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.

[75 FR 10167, Mar. 5, 2010]

§ 522.2220 Sulfadimethoxine injection.

(a)(1) *Specifications.* Sulfadimethoxine injection containing 400 milligrams per milliliter.

(2) *Sponsor.* (i) See No. 000069 in § 510.600(c) of this chapter for conditions of use as in paragraphs (a)(3)(i) through (a)(3)(iii) of this section.

(ii) See No. 057561 for conditions of use as in paragraph (a)(3) of this section.